CN109912692A - Seven ring aldehyde of YIGSK modification, preparation, anti-thrombus activity and application - Google Patents

Seven ring aldehyde of YIGSK modification, preparation, anti-thrombus activity and application Download PDF

Info

Publication number
CN109912692A
CN109912692A CN201711314627.4A CN201711314627A CN109912692A CN 109912692 A CN109912692 A CN 109912692A CN 201711314627 A CN201711314627 A CN 201711314627A CN 109912692 A CN109912692 A CN 109912692A
Authority
CN
China
Prior art keywords
tetrahydro
ile
gly
lys
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201711314627.4A
Other languages
Chinese (zh)
Other versions
CN109912692B (en
Inventor
赵明
彭师奇
石林峄
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Capital Medical University
Original Assignee
Capital Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Capital Medical University filed Critical Capital Medical University
Priority to CN201711314627.4A priority Critical patent/CN109912692B/en
Publication of CN109912692A publication Critical patent/CN109912692A/en
Application granted granted Critical
Publication of CN109912692B publication Critical patent/CN109912692B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses seven ring aldehyde of the Tyr-Ile-Gly-Ser-Lys of following formula modification, i.e. (2 ' S, 5 ' S)-tetrahydro pyrazine [1 ', 2 ': 1,6] and bis- { (1R- methylene-Tyr-Ile-Gly-Ser-Lys) -2,3,4,9- tetrahydro -1H- pyridine [3,4-b] diindyl } -1 ', 4 '-diketone, disclose its preparation method, its anti-arterial thrombus activity is disclosed, thus the invention discloses it to prepare the application in anti-arterial thrombus drug.

Description

Seven ring aldehyde of YIGSK modification, preparation, anti-thrombus activity and application
Technical field
(2 ' S, 5 ' S)-tetrahydro pyrazine [1 ', 2 ': 1,6] of the present invention and bis- { (1R- methylene-Tyr- Ile- Gly-Ser-Lys) -2,3,4,9- tetrahydro -1H- pyridine [3,4-b] diindyl } -1 ', 4 '-diketone, it is related to its preparation method, It is related to its anti-arterial thrombus activity, thus the present invention relates to it to prepare the application in anti-arterial thrombus drug.The invention belongs to In biomedicine field.
Background technique
Thrombosis is ischemic heart disease, the common pathology of ishemic stroke and phlebothrombosis.In the world, it lacks Death toll caused by hemorrhagic heart disease and ishemic stroke accounts for the 1/4 of whole Died Of Disease numbers.And phlebothrombosis is then not Developed country, medium-developed country and the highly developed main Disease Spectrum of country.Thrombus can make a series of relevant diseases Disease deteriorates, such as the blocking thrombus of the biomaterial pipe seldom occurred can be to change pipe repeatedly, or receive thromboembolism treatment or length The patient that phase receives anticoagulant therapy, which brings, is difficult to expect consequence, can cause to receive percutaneous coronary intervention treatment future trouble Person's embolism again, can with heparin-induced thrombocytopenia shape, and curved coronary artery thrombosis can cause it is acute Coronary syndrome.In addition, thrombosis is the complication of related disease, for example, bulk cerebral venous thrombosis with epileptics The complication of early stage pregnant woman, and stent thrombosis are the serious complication of percutaneous coronary intervention treatment patient.It can See, invents novel antithrombotic reagent with clinical importance.
B-carboline is the important pharmacophore for inhibiting thrombus.However B-carboline, such as 3S-1,2,3,4- tetrahydro-beta-carboline -3- Carboxylic acid will obtain anti-arterial thrombus purpose, not only need to be injected intravenously, and dosage needs 5 μm of ol/kg.From 3S-1,2,3,4- From the point of view of tetrahydro-β-anti-arterial thrombus of carboline -3- carboxylic acid, both expected to change into intravenous injection it is oral, and expect depressant Amount.Inventor assumes that two B-carboline pharmacophores merge, such as two (1R, 3S) -1- carbonyl methyl -2,3,4,9- tetrahydro -1H- Pyrido [3,4-b] indole -3-carboxylic acid's intermolecular condensation is (2 ' S, 5 ' S)-tetrahydro pyrazine [1 ', 2 ': 1,6] and bis- { (1R- carbonyls Methyl) -2,3,4,9- tetrahydro -1H- pyridine [3,4-b] diindyl -1 ', 4 '-diketone Ying Youqiang oral antithrombotic acitivity.Hair Bright people it is further assumed that, toward this novel seven rings aldehyde aldehyde radical connection Tyr-Ile-Gly-Ser-Lys should have it is stronger oral anti- Thrombus activity.According to this hypothesis, the present invention is inventors herein proposed.
Summary of the invention
First content of the invention is to provide (2 ' S, 5 ' S)-tetrahydro pyrazine [1 ', 2 ': 1,6] of following formula and bis- { (1R- Methylene-Tyr-Ile-Gly-Ser-Lys) -2,3,4,9- tetrahydro -1H- pyridine [3,4-b] diindyl } -1 ', 4 '-diketone.
Second content of the invention is to provide (2 ' S, 5 ' S)-tetrahydro pyrazine [1 ', 2 ': 1,6] and bis- { (1R- methylene- Tyr-Ile-Gly-Ser-Lys) -2,3,4,9- tetrahydro -1H- pyridine [3,4-b] diindyl } -1 ', 4 '-diketone preparation method, This method comprises:
1) L-Trp benzyl ester is subjected to Pictet- with 1,1,3,3- tetramethoxy propane under trifluoroacetic catalysis Spengler condensation, obtains (1R, 3S) -1- (dimethoxy-ethyl -2- base) -2,3,4,9- tetrahydro-beta-carboline -3- benzyl carboxylate (1)；
2) (1R, 3S) -1- (dimethoxy-ethyl -2- base) -2,3,4,9- tetrahydro-beta-carboline -3- benzyl carboxylate in methyl alcohol Ester hydrogenolysis under Pd/C catalysis takes off benzyl and obtains (1R, 3S) -1- (dimethoxy ethyl -2- base) -2,3,4,9- tetrahydro-beta-carboline -3- Carboxylic acid (2)；
3) in the presence of benzotriazole-N, N, N', N'- tetramethylurea hexafluorophosphoric acid ester (HBTu), (1R, 3S) -1- (two - 2 base of methoxyethyl) -2,3,4,9- tetrahydro-beta-carboline -3- carboxylic acid is intermolecular in anhydrous DMF (N,N-dimethylformamide) Condensation is (2 ' S, 5 ' S)-tetrahydro pyrazine [1 ', 2 ': 1,6] and bis- { (1R- dimethoxy ethyl -2- base) -2,3,4,9- tetrahydros - 1H- pyridine [3,4-b] diindyl } -1 ', 4 '-diketone (3)；
4) use glacial acetic acid for solvent, concentrated hydrochloric acid and water be catalyst (2 ' S, 5 ' S)-tetrahydro pyrazine [1 ', 2 ': 1,6] simultaneously The conversion of bis- { (1R- dimethoxy ethyl -2- base) -2,3,4,9- tetrahydro -1H- pyridine [3,4-b] diindyls } -1 ', 4 '-diketone (3) For (2 ' S, 5 ' S)-tetrahydro pyrazine [1 ', 2 ': 1,6] and bis- { (1R- carbonyl methyl) -2,3,4,9- tetrahydro -1H- pyridines [3,4-b] Diindyl } -1 ', 4 '-diketone (4)；
5) use dicyclohexylcarbodiimide for condensing agent, I-hydroxybenzotriazole is the method for the liquid phase condensations of catalyst Synthesize HClTyr-Ile-Gly-Ser-Lys (Cbz)-OBzl；
It 6) is that HClTyr-Ile-Gly-Ser-Lys (Cbz)-OBzl is connected to (2 ' by reducing agent with sodium cyanoborohydride S, 5 ' S)-tetrahydro pyrazine [1 ', 2 ': 1,6] and bis- { (1R)-[1- carbonyl methyl] -2,3,4,9- tetrahydro -1H- pyridine [3,4-b] is simultaneously Indoles } -1 ', 4 '-diketone (4) aldehyde radical on, synthesis (2 ' S, 5 ' S)-tetrahydro pyrazine [1 ', 2 ': 1,6] and it is bis- (1R)-[1- Asias First-Tyr-Ile-Gly-Ser-Lys (Cbz)-OBzl] -2,3,4,9- tetrahydro -1H- pyridine [3,4-b] diindyl } -1 ', 4 ' - Diketone (5)；
7) simultaneously double in trifluoracetic acid and in the mixed solvent (2 ' S, 5 ' S)-tetrahydro pyrazine [1 ', 2 ': 1,6] of trifluoromethanesulfonic acid { [1R- methylene-Tyr-Ile-Gly-Ser-Lys (Cbz)-OBzl] -2,3,4,9- tetrahydro -1H- pyridine [3,4-b] diindyl } - 1 ', 4 '-diketone (5) removing benzyloxycarbonyl group and benzyl ester obtain (2 ' S, 5 ' S)-tetrahydro pyrazine [1 ', 2 ': 1,6] and bis- { (1R- methylenes - Tyr-Ile-Gly-Ser-Lys) -2,3,4,9- tetrahydro -1H- pyridine [3,4-b] diindyl } -1 ', 4 '-diketone (6).
Third content of the invention is evaluation (2 ' S, 5 ' S)-tetrahydro pyrazine [1 ', 2 ': 1,6] and bis- { (1R- methylenes- Tyr-Ile-Gly-Ser-Lys) -2,3,4,9- tetrahydro -1H- pyridine [3,4-b] diindyl } -1 ', 4 '-diketone anti-arterial blood Bolt effect.
Detailed description of the invention
Fig. 1 (2 ' S, 5 ' S)-tetrahydro pyrazine [1 ', 2 ': 1,6] and bis- { (1R- methylene-Tyr-Ile-Gly-Ser-Lys)- 2,3,4,9- tetrahydro -1H- pyridine [3,4-b] diindyls } -1 ', 4 '-diketone synthetic route (i) methylene chloride, trifluoracetic acid； (ii)CH3OH, Pd/C, H2；(iii) HBTu, NMM, anhydrous DMF；(iv)H2O, glacial acetic acid, concentrated hydrochloric acid；(v) DCC, HOBt, NMM, THF；(vi) ethyl acetate solution (4M) of hydrogen chloride；(vii) methylene chloride, NaCNBH3, anhydrous MgSO4；(viii) Trifluoracetic acid, trifluoromethanesulfonic acid.
Specific embodiment
In order to which the present invention is further explained, a series of embodiments are given below.These embodiments be entirely it is illustrative, it Only be used to the present invention is specifically described, be not construed as limitation of the present invention.
Embodiment 1 prepares (1R, 3S) -1- (dimethoxy-ethyl -2- base) -2,3,4,9- tetrahydro-beta-carboline -3- benzyl carboxylate Ester (1)
180mL methylene chloride under ice bath, 10mL1,1,3,3- tetramethoxy propane and the trifluoroacetic mixed solution of 10mL Stir 40min.Later, 10.25g (34.86mmol) L-Trp-OBzl is added afterwards.14h, TLC is stirred at room temperature in reaction mixture (petrol ether/ethyl acetate=1:1) shows that L-Trp-OBzl disappears.Reaction solution is respectively with saturation NaHCO3Aqueous solution washes (40mL × 3), saturation NaCl aqueous solution is washed (40mL × 3), isolated methylene chloride anhydrous Na SO4Dry 12h, filtering, filtrate decompression Concentration, residue are purified (petrol ether/ethyl acetate=3:1) with silica gel column chromatography, obtain 5.12g (37%) title compound Object is brownish red grease.ESI-MS(m/e):393[M+H]-。
Embodiment 2 prepares (1R, 3S) -1- (dimethoxy-ethyl -2- base) -2,3,4,9- tetrahydro-beta-carboline -3- carboxylic acid (2)
To 5.12g (13.00mmol) (1R, 3S) -1- (dimethoxy-ethyl -2- base) -2,3,4,9- tetrahydro-beta-carboline - 500mg Pd/C is added in the solution of 3- benzyl carboxylate and 100mL methanol, is filled with hydrogen and 18h is stirred at room temperature, TLC (petroleum ether/ Ethyl acetate=1:1) show that 1 disappears, terminate reaction.Pd/C is filtered out, filtrate decompression is concentrated to dryness, and obtains 3.63g (92%) title Compound is glassy yellow grease.ESI-MS(m/e):303[M-H]-。
Embodiment 3 prepare (2 ' S, 5 ' S)-tetrahydro pyrazine [1 ', 2 ': 1,6] and it is bis- (1R- dimethoxy ethyl -2- base) -2, 3,4,9- tetrahydro -1H- pyridine [3,4-b] diindyl } -1 ', 4 '-diketone (3)
To 6.12g (20.13mmol) (1R, 3S) -1- (2,2- dimethoxy-ethyl -2- base) -2,3,4 under ice bath stirring, 3.00g (22.22mmol) HBTu is added in 9- tetrahydro-β-carboline -3- carboxylic acid (2) and the solution of 100mL anhydrous DMF.Then it uses The pH of reaction solution is adjusted to 8-9 by N-methyl morpholine, and point TLC (petrol ether/ethyl acetate=1:1) display 2 disappears afterwards for 24 hours for reaction It loses, terminates reaction.Reaction solution is concentrated under reduced pressure, and residue 150mL ethyl acetate dissolves.Later, respectively with saturation NaHCO3Water Solution is washed (30mL × 3), and saturation NaCl aqueous solution washes (30mL × 3), 5%KHSO4Aqueous solution is washed (3 0mL × 3), and NaCl is saturated Aqueous solution is washed (30mL × 3), and NaHCO is saturated3Aqueous solution is washed (30mL × 3), and saturation Na Cl aqueous solution washes (30mL × 3).Acetic acid The methacrylate layer dry 12h of anhydrous sodium sulfate, filtering, filtrate decompression concentration.Obtained dark yellow solid is separated with silica gel column chromatography (petrol ether/ethyl acetate=2:1) obtains 1.14g (10%) title compound, is yellow solid.ESI-MS(m/e):573[M+ H]+；1HNMR(300MHz,DMSO-d6) δ/ppm=11.08 (s, 2H), 7.39 (d, J=7.5Hz, 2H), 7.34 (d, J= 8.1Hz, 2H), 7.08 (t, J=7.2Hz, 2H), 6.97 (t, J=7.2Hz, 2H), 5.93 (dd, J1=3.6Hz, J2= 9.0Hz,2H),4.62(dd,J1=3.3Hz, J2=11.4Hz, 2H), 4.53 (t, J=4.8Hz, 2H), 3.34 (s, 6H), 3.26 (s,6H),3.20(m,2H),2.79 (m,2H),2.24(m,4H)。
Embodiment 4 prepares (2 ' S, 5 ' S)-tetrahydro pyrazine [1 ', 2 ': 1,6] and bis- { (1R- carbonyl methyl) -2,3,4,9- four Hydrogen -1H- pyridine [3,4-b] diindyl } -1 ', 4 '-diketone (4)
To 380mg (0.66mmol) (2 ' S, 5 ' S)-tetrahydro pyrazine [1 ', 2 ': 1,6] and bis- { (1R- bis- under ice bath and stirring Methoxyethyl -2- base) -2,3,4,9- tetrahydro -1H- pyridine [3,4-b] diindyl } -1 ', 4 '-diketone (3) and 9mL glacial acetic acid 6mL water and 3mL concentrated hydrochloric acid are added in solution, stirs 2h, TLC shows that (petrol ether/ethyl acetate=1:1) 3 disappears, and terminates anti- It answers.Under ice bath, reacting liquid pH value is adjusted to 7 with NaOH aqueous solution (2M).Obtained solution be extracted with ethyl acetate (50 mL × 3), combined ethyl acetate layer is respectively with saturation NaHCO3Aqueous solution is washed (30mL × 3), saturation NaCl aqueous solution wash (30mL × 3), 12h is dried with anhydrous sodium sulfate in ethyl acetate phase, filters off sodium sulphate, and filtrate decompression is concentrated to get 288mg (90%) Title compound is yellow solid.ESI-MS(m/e):481[M+H]+；1H-NMR(300MHz, DMSO-d6) δ/ppm= 10.95 (s, 2H), 9.79 (m, 2H), 7.42 (d, J=8.1Hz, 2H), 7.38 (d, J=7.5Hz, 2H), 7.10 (t, J= 6.9Hz, 2H), 6.99 (t, J=6.9Hz, 2H), 6.22 (dd, J1=3.6Hz, J2=9.0Hz, 2H), 4.67 (dd, J1= 3.3Hz,J2=11.4Hz, 2H), 3.26 (m, 2H), 3.11 (m, 4H), 2.84 (m, 2H).
Embodiment 5 prepares Boc-Ile-Gly-OBzl
2.70g is added into the solution of 4.62g (20.00mmol) Boc-Ile and 150mL anhydrous tetrahydro furan under ice bath (20.00mmol) HOBt is added 4.53g (22.00mmol) DCC after stirring 5min, stirs 30min under ice bath, obtain reaction solution A.Under ice bath, 4.84g (24.00mmol) HClGly-OBzl is added in reaction solution A, pH value is adjusted with N- methyl morpholine and arrives 9.Anti- 20h is stirred at room temperature in reaction mixture, and TLC (petrol ether/ethyl acetate=2:1) shows that Boc-Ile disappears.Filter out reaction solution In insoluble matter, filtrate decompression concentration, residue 150mL ethyl acetate dissolves, and filters off insoluble colorless solid, filtrate difference With saturation NaHCO3Aqueous solution is washed (30mL × 3), and saturation NaCl aqueous solution washes (30mL × 3), 5%KHSO4Aqueous solution washes (30mL × 3), saturation NaCl aqueous solution is washed (30mL × 3), is saturated NaHCO3Aqueous solution is washed (30mL × 3), and saturation NaCl aqueous solution is washed (30mL × 3), the obtained ethyl acetate phase dry 12h of anhydrous sodium sulfate, filter off sodium sulphate, and filtrate decompression concentration obtains 7.16g (95%) title compound is faint yellow solid.ESI-MS(m/e):379[M+H]+。
Embodiment 6 prepares HClIle-Gly-OBzl
7.16g (18.94mmol) Boc-Ile-Gly-OBzl 20mL anhydrous ethyl acetate is dissolved, then under ice bath The ethyl acetate solution (4M) of 80mL hydrogen chloride is added into solution, 6h, TLC (petrol ether/ethyl acetate=2:1) is stirred at room temperature Show that Boc-Ile-Gly-OBzl disappears.Reaction solution is concentrated under reduced pressure, residue depressurizes dense again after being redissolved with anhydrous ethyl acetate Contracting, then redissolved with anhydrous ethyl acetate.The operation is at least repeated 3 times.Final residual object is washed with anhydrous ether, obtains 5.78g (97%) title compound is faint yellow solid.
Embodiment 7 prepares Boc-Tyr-Ile-Gly-OBzl
According to the method for embodiment 5 from 2.81g (10.00mmol) Boc-Tyr and 3.78g (12.00mmol) HCl Ile-Gly-OBzl obtains 4.77g (88%) title compound, is colorless solid.ESI-MS(m/e):542[M+H]+。
Embodiment 8 prepares Boc-Tyr-Ile-Gly
3.89g (97%) is obtained from 4.77g (8.82mmol) Boc-Tyr-Ile-Gly-OBzl according to the method for embodiment 2 Title compound is colorless solid.
Embodiment 9 prepares Boc-Ser-Lys (Cbz)-OBzl
According to the method for embodiment 5 from 2.04g (10.00mmol) Boc-Ser and 4.88g (12.00mmol) HClLys (Cbz)-OBzl obtains 4.76g (85%) title compound, is yellow solid.ESI-MS(m/e):557[M+H]+。
Embodiment 10 prepares HClSer-Lys (Cbz)-OBzl
3.15g is obtained from 3.70g (6.65mmol) Boc-Ser-Lys (Cbz)-OBzl according to the method for embodiment 6 (96%) title compound is colorless solid.
Embodiment 11 prepares Boc-Tyr-Ile-Gly-Ser-Lys (Cbz)-OBzl
According to the method for embodiment 5 from 2.50g (5.54mmol) Boc-Tyr-Ile-Gly and 3.27g (6.64 mmol) HClSer-Lys (Cbz)-OBzl obtains 2.95g (60%) title compound, is colourless powder.ESI-MS(m/e):891 [M +H]+。
Embodiment 12 prepares HClTyr-Ile-Gly-Ser-Lys (Cbz)-OBzl
It is obtained according to the method for embodiment 6 from 965mg (1.09mmol) Boc-Tyr-Ile-Gly-Ser-Lys (Cbz)-OBzl It is colorless solid to 858mg (96%) title compound.
Embodiment 13 prepares (2 ' S, 5 ' S)-tetrahydro pyrazine [1 ', 2 ': 1,6] and bis- { [1R- methylene-Tyr-Ile-Gly- Ser-Lys (Cbz)-OBzl] -2,3,4,9- tetrahydro -1H- pyridine [3,4-b] diindyl } -1 ', 4 '-diketone (5)
By 166mg (0.35mmol) (2 ' S, 5 ' S)-tetrahydro pyrazine [1 ', 2 ': 1,6] and it is bis- (1R- carbonyl methyl) -2,3,4, 9- tetrahydro -1H- pyridine [3,4-b] diindyl } -1 ', 4 '-diketone (4) are dissolved in 15mL methylene chloride, with triethylamine tune under ice bath PH value is saved to 9.858mg (1.04mmol) HClTyr-Ile-Gly-Ser-Lys (Cbz)-OBzl is molten with 15mL methylene chloride It solves, pH value is adjusted to 9 with triethylamine under ice bath, is added drop-wise under ice bath in the dichloromethane solution of compound 4, adds 100mg MgSO4.After reaction mixture ice bath stirring 1h, 27mg NaCNBH is added every 1h3, 108mg NaCNBH is added altogether3.Later, TLC (methylene chloride/methanol=7:1) for 24 hours is stirred at room temperature and shows that compound 4 disappears, terminates reaction.Reaction solution is respectively with saturation NaHCO3Aqueous solution is washed (7mL × 3), and saturation NaCl aqueous solution washes (7mL × 3), and obtained methylene chloride mutually uses anhydrous sodium sulfate After dry 12h, sodium sulphate, filtrate decompression concentration are filtered off, obtained yellow solid silica gel column chromatography purifies (methylene chloride/first Alcohol=20:1), 50mg (7%) title compound is obtained, is faint yellow solid.ESI-MS(m/e):2030[M+H]+；1H-NMR (300MHz,DMSO-d6) δ/ppm=10.97 (s, 2H), 8.31 (m, 4H), 8.11 (m, 4H), 7.90 (m, 2H), 7.39~ 7.28(m,24H),7.01(m,10H),6.64(m,4H),5.88(m, 2H),5.10(m,4H),4.99(m,4H),4.89(t,J =5.4Hz, 2H), 4.63 (m, 2H), 4.39 (m, 2H), 4.23 (m, 4H), 3.76 (m, 4H), 3.56 (m, 4H), 3.39 (m, 2H), 3.21 (m, 2H), 2.94 (m, 8H), 2.89~2.55 (m, 10H), 1.99 (m, 4H), 1.68 (m, 4H), 1.37 (m, 4H),1.26(m,4H),1.01(m,4H),0.74(m,12H)。
Embodiment 14 prepares (2 ' S, 5 ' S)-tetrahydro pyrazine [1 ', 2 ': 1,6] and bis- { [1R- methylene-Tyr-Ile-Gly- Ser-Lys] -2,3,4,9- tetrahydro -1H- pyridine [3,4-b] diindyl } -1 ', 4 '-diketone (6)
By 50mg (0.02mmol) (2 ' S, 5 ' S)-tetrahydro pyrazine [1 ', 2 ': 1,6] and bis- { [1R- methylenes-under ice bath Tyr-Ile-Gly-Ser-Lys (Cbz)-OBzl] -2,3,4,9- tetrahydro -1H- pyridine [3,4-b] diindyl } -1 ', 4 '-diketone (5) it is dissolved with 1.5 mL trifluoroacetic acids.Later, 0.5mL trifluoromethanesulfonic acid is added, stirs 30min, TLC (methylene chloride under ice bath / methanol=7:1) the display disappearance of compound 5.Add 25mL anhydrous ether under ice bath into reaction mixture, stir 10min, stands, Incline supernatant.Residue adds 25mL anhydrous ether again, stirs 10min, stands, incline supernatant.The operation at least repeats 3 It is secondary.Obtained 5% acetate dissolution of yellow black solid 1mL, solution are purified with Sephadex, obtain 6mg (15%) title compound Object is faint yellow solid.ESI-MS(m/e):1315[M+H]+；1H-NMR(300 MHz,DMSO-d6) δ/ppm=12.80 (s, 2H), 10.82 (s, 2H), 9.33 (m, 4H), 8.50 (m, 4H), 8.26 (m, 2H), 7.37 (m, 4H), 7.14~6.94 (m, 8H),6.68(m,4H),5.77(m,2H),4.82(m,2H),4.53(m,2H), 4.27(m,2H),4.16(m,4H),3.79 (m,4H),3.56(m,6H),3.18(m,2H),2.96(m,8H),2.77(m, 10H),2.37(m,2H),2.17(m,2H), 1.74(m,4H),1.53(m,8H),1.34(m,4H),0.87(m,4H), 0.56(m,12H)。
Embodiment 15 evaluates (2 ' S, 5 ' S)-tetrahydro pyrazine [1 ', 2 ': 1,6] and bis- { (1R- methylene-Tyr-Ile-Gly- Ser-Lys) -2,3,4,9- tetrahydro -1H- pyridine [3,4-b] diindyl } -1 ', 4 '-diketone (6) anti-arterial thrombus effect
Experimental material: aspirin (Aspirin, CAS:50-78-2, article No.: 298969, the limited public affairs of lark prestige science and technology Department), urethane (CAS:51-79-6, article No.: 30191228, Sinopharm Chemical Reagent Co., Ltd.), heparin sodium (CAS: 9041-08-1, article No.: 542858, lark prestige Science and Technology Ltd.), physiological saline (Shijiazhuang Siyao Co., Ltd), anhydrous second Ether (Beijing chemical reagents corporation), silicone oil (Beijing chemical reagents corporation), two citric acid monohydrate trisodiums (CMCNa, article No.: 20170713, Beijing Chemical Plant).
Experimental animal: SD strain rats, male, 200 ± 20g tie up the limited public affairs of tonneau China experimental animal technology purchased from Beijing Department.
Experimental method: experiment bypasses tuft method using arteria carotis communis-vena jugularis externa extracorporal circulatory system.
Grouping and dosage: (2 ' S, 5 ' S)-tetrahydro pyrazine [1 ', 2 ': 1,6] and bis- { (1R- methylene-Tyr-Ile-Gly- Ser-Lys) -2,3,4,9- tetrahydro -1H- pyridine [3,4-b] diindyl } dosage of -1 ', 4 '-diketone (abbreviation compound 6) is 0.1 μm of ol/kg, the dosage of positive control aspirin are 167 μm of ol/kg, negative control 0.5%CMCNa.
The dosage form of reagent: anesthetic is the normal saline solution (20%) of urethane, and anti-coagulants is the physiology salt of heparin sodium Aqueous solution (42mg/100mL), compound 6 are the suspension of 0.5%CMCNa, and aspirin is the suspension of 0.5%CMCNa.
Bypass intubation: the bypass intubation of right jugular vein and left neck artery is 1.0mm, outer diameter 2.0mm, length 10.0 by internal diameter The polyethylene pipe of cm is constituted.The tubule pulled into as angle is heated in their one end, to be inserted into right jugular vein and left neck artery. They constitute the both ends of bypass intubation.It is 3.5mm that the middle section being intubated, which is bypassed, by internal diameter, and the polyethylene pipe of a length of 8.0cm is constituted.
Thrombus load line: a length of 6.0cm, weight are the crude silk thread in surface of 4.0 ± 0.1mg.
Bypass intubation assembling: three sections of Interior Wall of Polythene Pipe use diethyl ether solution (1%) silanization of silicone oil, dry completely Afterwards, silk thread is placed in the polyethylene pipe of middle section in arteria carotis intubation direction, three sections of polyethylene pipes is assembled and consolidated using sealed membrane It is fixed, heparin need to be full of before intubation in pipe.
Experimental implementation: according to the dosage of 0.1 μm of ol/kg by the suspension of the CMCNa of compound 6 with 0.3mL/100g weight To rat oral gavage, the suspension of the CMCNa of aspirin is given greatly with 0.3mL/100g weight according to the dosage of 167 μm of ol/kg Mouse stomach-filling, and by CMCNa with 0.3mL/100g weight to rat oral gavage.The urethane solution of intraperitoneal injection 20% after 30min Anaesthetized (0.7mL/100g).Rat is fixed on plate by dorsal position, cuts off skin of neck, separates right common carotid artery and left neck Outer vein respectively ligatures the distal end of right common carotid artery and left vena jugularis externa with surgical thread, in quiet outside exposed left neck Arteries and veins cuts a V-shape osculum, and the vein end angle of the bypass intubation made above is inserted into the proximal part of left vena jugularis externa opening, is inserted Blood vessel and polyethylene pipe are fixed with surgical thread at pipe.Pass through the accurate note of bypass intubation according to the dosage of 0.1mL/100g weight Enter heparin sodium water solution, syringe does not withdraw polyethylene pipe.Right common carotid artery proximal part is clamped with artery clamp, in exposed artery On cut a V-shape osculum, the tip of polyethylene pipe is removed from syringe, the proximal part of right common carotid artery is inserted a tube into, uses hand Art line fixes arteries and polyethylene pipe, unclamps artery clamp, establishes extracorporal circulatory system bypass.Rat temperature and bypass is maintained to insert Blood flow is unobstructed in pipe, and vein end is first intubated to cut whether observation blood circulation is smooth after extracorporal circulatory system 15min, from moving for intubation Arteries and veins end removal of thromboses line weighs and records thrombus weight after sucking the blood on silk thread on filter paper, represent anti-arterial thrombus activity.Number It is counted according to using t inspection.Experimental data is shown in Table 1.
Table 1 statistics indicate that, (2 ' S, 5 ' the S)-tetrahydro pyrazine [1 ', 2 ': 1,6] and double under 0.1 μm of ol/kg oral dose { (1R)-[1- methylene-Tyr-Ile-Gly-Ser-Lys] -2,3,4,9- tetrahydro -1H- pyridine [3,4-b] diindyl } -1 ', 4 ' - Diketone (abbreviation compound 6) can conspicuousness inhibition rat formation thrombus.This effective dose is intravenous injection 3S-1,2,3,4- tetra- The 1/50 of hydrogen-B-carboline -3- carboxylic acid antithrombotic 5 μm of ol/kg of effective dose.The compound of the present invention 6 not only by 3S-1,2,3, The intravenous injection of 4- tetrahydro-beta-carboline -3- carboxylic acid is changed into oral, and reduces dosage.As it can be seen that the present invention have it is unexpected Technical effect.
The anti-arterial thrombus activity of 1 compound 6 of table
Compound Dosage Thrombus weight (mean value ± SD mg)
0.5%CMCNa 3mL/kg 29.29±4.94
Aspirin 167μmol/kg 18.98±4.24a
Compound 6 0.1μmol/kg 21.36±4.03a
And 0.5%CMCNa ratio P < 0.01 a)；N=8.

Claims (3)

1. the Tyr-Ile-Gly-Ser-Lys of following formula modifies seven ring aldehyde, i.e. (2 ' S, 5 ' S)-tetrahydro pyrazine [1 ', 2 ': 1,6] is simultaneously double { (1R- methylene-Tyr-Ile-Gly-Ser-Lys) -2,3,4,9- tetrahydro -1H- pyridine [3,4-b] diindyl } -1 ', 4 '-two Ketone,
2. the Tyr-Ile-Gly-Ser-Lys of claim 1 modifies the preparation method of seven ring aldehyde, this method comprises:
1) L-Trp benzyl ester is subjected to Pictet- with 1,1,3,3- tetramethoxy propane under trifluoroacetic catalysis Spengler condensation, obtains (1R, 3S) -1- (dimethoxy-ethyl -2- base) -2,3,4,9- tetrahydro-beta-carboline -3- benzyl carboxylate (1)；
2) (1R, 3S) -1- (dimethoxy-ethyl -2- base) -2,3,4,9- tetrahydro-beta-carboline -3- benzyl carboxylate exists in methyl alcohol Pd/C is catalyzed the de- benzyl of lower hydrogenolysis and obtains (1R, 3S) -1- (dimethoxy ethyl -2- base) -2,3,4,9- tetrahydro-beta-carboline -3- carboxylic acid (2)；
3) in the presence of benzotriazole-N, N, N', N'- tetramethylurea hexafluorophosphoric acid ester (HBTu), (1R, 3S) -1- (dimethoxy - 2 base of ethyl) -2,3,4,9- tetrahydro-beta-carboline -3- carboxylic acid intermolecular condensation in anhydrous DMF (N,N-dimethylformamide) is (2 ' S, 5 ' S)-tetrahydro pyrazine [1 ', 2 ': 1,6] and bis- { (1R- dimethoxy ethyl -2- base) -2,3,4,9- tetrahydro -1H- pyridines [3,4-b] diindyl } -1 ', 4 '-diketone (3)；
4) use glacial acetic acid for solvent, concentrated hydrochloric acid and water are that catalyst (2 ' S, 5 ' S)-tetrahydro pyrazine [1 ', 2 ': 1,6] is simultaneously double { (1R- dimethoxy ethyl -2- base) -2,3,4,9- tetrahydro -1H- pyridine [3,4-b] diindyl } -1 ', 4 '-diketone (3) are converted into (2 ' S, 5 ' S)-tetrahydro pyrazine [1 ', 2 ': 1,6] and bis- { (1R- carbonyl methyl) -2,3,4,9- tetrahydro -1H- pyridine [3,4-b] and Yin Diindyl } -1 ', 4 '-diketone (4)；
5) use dicyclohexylcarbodiimide for condensing agent, I-hydroxybenzotriazole is the method synthesis of the liquid phase condensations of catalyst HCl·Tyr-Ile-Gly-Ser-Lys(Cbz)-OBzl；
6) to be reducing agent with sodium cyanoborohydride be connected to HClTyr-Ile-Gly-Ser-Lys (Cbz)-OBzl (2 ' S, 5 ' S)-tetrahydro pyrazine [1 ', 2 ': 1,6] and bis- { (1R)-[1- carbonyl methyl] -2,3,4,9- tetrahydro -1H- pyridine [3,4-b] and Yin Diindyl } -1 ', 4 '-diketone (4) aldehyde radical on, synthesis (2 ' S, 5 ' S)-tetrahydro pyrazine [1 ', 2 ': 1,6] and bis- { (1R)-[1- methylenes - Tyr-Ile-Gly-Ser-Lys (Cbz)-OBzl] -2,3,4,9- tetrahydro -1H- pyridine [3,4-b] diindyl } -1 ', 4 '-diketone (5)；
7) simultaneously double in trifluoracetic acid and in the mixed solvent (2 ' S, 5 ' S)-tetrahydro pyrazine [1 ', 2 ': 1,6] of trifluoromethanesulfonic acid { [1R- methylene-Tyr-Ile-Gly-Ser-Lys (Cbz)-OBzl] -2,3,4,9- tetrahydro -1H- pyridine [3,4-b] diindyl } - 1 ', 4 '-diketone (5) removing benzyloxycarbonyl group and benzyl ester obtain (2 ' S, 5 ' S)-tetrahydro pyrazine [1 ', 2 ': 1,6] and bis- { (Asias 1R- First-Tyr-Ile-Gly-Ser-Lys) -2,3,4,9- tetrahydro -1H- pyridine [3,4-b] diindyl } -1 ', 4 '-diketone (6).
3. the Tyr-Ile-Gly-Ser-Lys of claim 1 modifies seven ring aldehyde and is preparing the application in anti-arterial thrombus drug.
CN201711314627.4A 2017-12-12 2017-12-12 YIGSK modified heptacyclic aldehyde, preparation, antithrombotic activity and application thereof Active CN109912692B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201711314627.4A CN109912692B (en) 2017-12-12 2017-12-12 YIGSK modified heptacyclic aldehyde, preparation, antithrombotic activity and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201711314627.4A CN109912692B (en) 2017-12-12 2017-12-12 YIGSK modified heptacyclic aldehyde, preparation, antithrombotic activity and application thereof

Publications (2)

Publication Number Publication Date
CN109912692A true CN109912692A (en) 2019-06-21
CN109912692B CN109912692B (en) 2021-02-12

Family

ID=66957308

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201711314627.4A Active CN109912692B (en) 2017-12-12 2017-12-12 YIGSK modified heptacyclic aldehyde, preparation, antithrombotic activity and application thereof

Country Status (1)

Country Link
CN (1) CN109912692B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110577571A (en) * 2018-06-08 2019-12-17 首都医科大学 YIGSK modified heptacyclic aldehyde, synthesis, antithrombotic activity and application thereof
CN115353546A (en) * 2022-05-19 2022-11-18 首都医科大学 Preparation and application of oligopeptide-modified bis-indolylethyl-beta-carboline-3-carboxylic acid

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103450334A (en) * 2012-05-29 2013-12-18 首都医科大学 RGD peptide-modified carbolino-hexahydropyrazine-1,4-diketones and their preparation method, antithrombotic effect and use
CN105218634A (en) * 2014-06-11 2016-01-06 首都医科大学 The indoles quinolizine that YIGSR modifies, its preparation, nanostructure, active and application

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103450334A (en) * 2012-05-29 2013-12-18 首都医科大学 RGD peptide-modified carbolino-hexahydropyrazine-1,4-diketones and their preparation method, antithrombotic effect and use
CN105218634A (en) * 2014-06-11 2016-01-06 首都医科大学 The indoles quinolizine that YIGSR modifies, its preparation, nanostructure, active and application

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DILINUR SHABITOFU等: "Antiplatelet Aggregation Effects of YIGSK and RGD Containing Peptides", 《JOURNAL OF CHINESE PHARMACEUTICAL SCIENCES》 *
HAIMEI ZHU等: "Design, synthesis and evaluation of a novel π-π stacking nano-intercalator as an anti-tumor agent", 《MEDCHEMCOMM》 *
HAIMEI ZHU等: "Docking of THPDTPI: to explore P-selectin as a common target of anti-tumor, anti-thrombotic and anti-inflammatory agent", 《ONCOTARGET》 *
马英: "《药物化学》", 31 August 2012, 河南科学技术出版社 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110577571A (en) * 2018-06-08 2019-12-17 首都医科大学 YIGSK modified heptacyclic aldehyde, synthesis, antithrombotic activity and application thereof
CN110577571B (en) * 2018-06-08 2021-06-08 首都医科大学 YIGSK modified heptacyclic aldehyde, synthesis, antithrombotic activity and application thereof
CN115353546A (en) * 2022-05-19 2022-11-18 首都医科大学 Preparation and application of oligopeptide-modified bis-indolylethyl-beta-carboline-3-carboxylic acid

Also Published As

Publication number Publication date
CN109912692B (en) 2021-02-12

Similar Documents

Publication Publication Date Title
CN109912597A (en) Seven ring aldehyde, synthesis, anti-thrombus activity and application
CN107686483B (en) Heptacyclic acetals, their preparation, antithrombotic activity and use
RU2660901C2 (en) New compounds having triple activities of thrombolysis, antithrombotic and radical scavenging, and synthesis, nano-structure and use thereof
CN101899084A (en) (3S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid kyrine conjugate, preparation method and application thereof
CN104530199B (en) A kind of tumor protein p53 and its preparation method and application
CN109912693A (en) Seven ring aldehyde of RGDS modification, synthesis, anti-thrombus activity and application
CN110577530B (en) Heptacyclic aldehyde, its synthesis, antithrombotic activity and use
CN109912692A (en) Seven ring aldehyde of YIGSK modification, preparation, anti-thrombus activity and application
CN109912694A (en) Seven ring aldehyde of RGDF modification, preparation, anti-thrombus activity and application
CN109912695A (en) Seven ring aldehyde of RGDV modification, preparation, anti-thrombus activity and application
CN110577583B (en) RGDF modified heptacyclic aldehyde, its synthesis, antithrombotic activity and application
CN104761610A (en) Novel alpha-hederin derivative and preparation method and use thereof
CN110563799B (en) RGDS modified heptacyclic aldehyde, synthesis, antithrombotic activity and application thereof
CN108948146A (en) 1R- methyl-beta-tetrahydro carboline acyl-K (ARPAK)-RGDV, synthesis, activity and application
CN107459557B (en) Levoviru-2-oxyacetyl-GRPAK, its synthesis, activity and application
CN110577571B (en) YIGSK modified heptacyclic aldehyde, synthesis, antithrombotic activity and application thereof
CN110577582B (en) LDV modified heptacyclic aldehyde, synthesis, antithrombotic activity and application thereof
CN110577569B (en) RGDV-modified heptacyclic aldehyde, synthesis, antithrombotic activity and application thereof
CN113754662A (en) RS-heptacyclic aldehyde, its synthesis, activity and application
CN107698660B (en) imidazopyridine-6-formyl-Lys (Lys) -oligopeptides, their synthesis, activity and uses
CN111995661A (en) Ethyl ARPAK modified bis-carbolino-piperazinediones, preparation, activity and application thereof
CN107459556B (en) L-vitamin C-2-oxyacetyl-PAKPAK, its synthesis, activity and application
CN107459553B (en) Levovitamin C-2-oxyacetyl-PAK, its synthesis, activity and application
CN106349332B (en) imidazopyridinyl-KRGDV, its synthesis, antithrombotic activity and use
CN108948155A (en) 1R- methyl-beta-tetrahydro carboline acyl-K (QRPAK)-RGDV, synthesis, activity and application

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant